Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Ligand Pharmaceuticals

3 Overlooked Stocks Positioned for the Next Market Rotation

Oxford Club strategist Marc Lichtenfeld highlights diversification beyond tech, spotlighting Ligand Pharmaceuticals, Aflac and Atlantic Union Bankshares as healthcare, insurance and banking stocks gaining quiet momentum.

MarketBeat

Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026

Investing in these three biotech stocks can offer investors with a high-risk profile the opportunity to generate outsized gains over the next decade.

Barchart

3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing

Explore three small-cap stocks with 'Strong Buy' ratings that are poised for significant growth as economic conditions hint at a potential soft landing.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Benzinga

Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know

Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00. Shares of Ligand Pharmaceuticals are trading up 1.79% over the last 24 hours, at $92.20 per share.

Benzinga

Recap: Ligand Pharmaceuticals Q4 Earnings

Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Organisations

US Food and Drug Administration

63 stories

Apellis Pharmaceuticals

17 stories

BioMarin

14 stories

Biomarin Pharmaceutical

12 stories

KNSA

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.